Published On: March 8, 2019Categories: Company News, Press Releases

GHP Announces the 2019 Biotechnology Awards Winners

GAINESVILLE, GA – March 08 , 2019 – AEON Global Health Corp. (OTC QB: AGHC), a leading healthcare company was recognized as  “Leaders in Cancer Genomics Diagnostics 2019” and received the “GHP Award for Excellence in Toxicology Diagnostics” as announced by the UK-based GHP Magazine. GHP Magazine announced the winners of the 2019 Biotechnology Awards. Covering a variety of verticals, including bio agriculture, bio services, bio industrial and biopharmaceutical, the biotechnology market will be under the microscope in GHP Magazine’s, 2019 Biotechnology Awards.

“We are honored that our work in the fields of Cancer Genomics and Toxicology has been recognized by the prestigious GHP Magazine,” said Sonny Roshan, Chairman AEON Global Health. “At AEON, we are strongly committed to deliver the highest levels of service, innovation, and value to our customers that enable people to live better lives,” he added.

Steve Simpson, Awards Coordinator, commented on the awards and their deserving winners: “Through this awards program, GHP honors a range of companies active within the sector. From leading chemists, clinicians, researchers, manufacturers, consultants, engineers, to those providing peripherals and specialist services, all of my winners deserve hearty congratulations, and I wish them the best of luck for the future.”

Boasting impressive market value growth with no signs of slowing, endeavors in biotechnology continue to make advancements in the laboratories as well as in the boardrooms, advancements which the lives of all, across the globe. It is for this reason, we at GHP are dedicated to bringing your accomplishments to the forefront of the community with our award platform.

To find out more about the award winners, please visit to access the winners supplement.



AEON Global Health is a publicly traded, Joint Commission accredited, growth-oriented healthcare company that provides a broad portfolio of market-leading solutions that are well-aligned with long-term healthcare trends. Our mission is to help in the prevention, diagnosis, and treatment of diseases by providing healthcare professionals with clinically actionable information that promotes patient‐centric, personalized medical care. Operating out of a modern 30,000 square-foot facility in suburban Atlanta, the Company provides a comprehensive menu of healthcare services in Cancer Genomics, Pharmacogenomics, Toxicology, Infectious Diseases, Blood Wellness, Carrier Screening and Respiratory Pathogen Detection.


Global Health and Pharma magazine is a global information sharing platform & a multi-disciplinary member’s community. The publication was established to enhance communication networks & collaboration across all themes and disciplines within three main categories; Human, Animal & Environmental Health.

Except for historical information, the matters discussed in this press release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this release, words such as “believe”, “anticipate” think”, “intend”, “plan”, “will be”, “expect” or similar expressions identify such forward looking statements. In addition, such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, for example, the markets for the Company’s services, costs of and services, other expenses, government regulations, litigation, and general business conditions. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.